中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
17期
23-24,25
,共3页
头孢拉定%缓释片%Higuchi方程
頭孢拉定%緩釋片%Higuchi方程
두포랍정%완석편%Higuchi방정
cefradine%sustained-release tablets%Higuchi equation
目的：头孢拉定为第1代半合成头孢菌素，为了满足临床特殊用途，进行缓释片的研究。方法采用羟丙甲纤维素（HPMC）、丙烯酸树脂Ⅱ号等缓释材料制备头孢拉定缓释制剂，并考察丙烯酸树脂Ⅱ号含量、剂型、释放介质等对体外累积释放率的影响。结果头孢拉定缓释片体外释药测定结果符合缓释制剂要求。结论头孢拉定缓释片与Higuchi方程拟合较好（在PH＝1.2人工胃液中线性回归系数为0.9887，在PH＝7.4人工肠液中为0.9935），是骨架溶蚀和药物扩散的综合效应过程。
目的：頭孢拉定為第1代半閤成頭孢菌素，為瞭滿足臨床特殊用途，進行緩釋片的研究。方法採用羥丙甲纖維素（HPMC）、丙烯痠樹脂Ⅱ號等緩釋材料製備頭孢拉定緩釋製劑，併攷察丙烯痠樹脂Ⅱ號含量、劑型、釋放介質等對體外纍積釋放率的影響。結果頭孢拉定緩釋片體外釋藥測定結果符閤緩釋製劑要求。結論頭孢拉定緩釋片與Higuchi方程擬閤較好（在PH＝1.2人工胃液中線性迴歸繫數為0.9887，在PH＝7.4人工腸液中為0.9935），是骨架溶蝕和藥物擴散的綜閤效應過程。
목적：두포랍정위제1대반합성두포균소，위료만족림상특수용도，진행완석편적연구。방법채용간병갑섬유소（HPMC）、병희산수지Ⅱ호등완석재료제비두포랍정완석제제，병고찰병희산수지Ⅱ호함량、제형、석방개질등대체외루적석방솔적영향。결과두포랍정완석편체외석약측정결과부합완석제제요구。결론두포랍정완석편여Higuchi방정의합교호（재PH＝1.2인공위액중선성회귀계수위0.9887，재PH＝7.4인공장액중위0.9935），시골가용식화약물확산적종합효응과정。
Objective Cefradine is the first generation of half synthetic cePhalosPorin. To study the cefradine sustain-release tablet for sPecific usage in the clinic. Methods Sustained-release materials,such as HPMC and Eudragit Ⅱwere adoPted to PrePare the cefra-dine sustained-release dosage forms,and the effects of acrylic resin content,dosage forms and release medium on the cumulative drug release were studied. Results The cefradine sustained-release tablets met the requirements of sustained-release. Conclusion The cefradine sustained-release tablets fit well with the Higuchi equation ( PH=1. 2,R2=0. 988 7,PH=7. 4,R2=0. 994 3 ) ,which is a comPrehensive Process of skeleton dissolution and drug diffusion.
